DMF is an Nrf2 activator with immunomodulating, as well as anti-inflammatory and anti-oxidative effects (55). Studies show that MS patients treated with DMF have reduced percentages of pro-inflammatory CD4+ and CD8+ T cells and an expansion of CD56bright NK cells and a modest increase in absolute numbers of CD56dim cells (55, 56). The gene discussed is CD4; the disease is myeloid sarcoma.